In a patient with type 2 diabetes who underwent a deceased donor kidney transplant 5 months ago, has hemoglobin A1c 10.2 % while on insulin glargine 7 units daily and metformin 500 mg at dinner, insulin‑to‑carbohydrate ratio 1 unit per 20 g carbohydrate, insulin sensitivity factor 1 unit per 50 mg/dL, fasting blood glucose 134 mg/dL, and lacks caregiver support, can basal insulin be discontinued and the patient be discharged on metformin alone?

No, Discontinuing Basal Insulin and Discharging on Metformin Alone is Not Appropriate

With an A1c of 10.2%, this patient requires intensification of therapy, not de-escalation—discontinuing insulin would be clinically inappropriate and potentially harmful to both graft and patient outcomes. 1

Why Insulin Cannot Be Discontinued

Severe Hyperglycemia Requires Insulin

• An A1c of 10.2% represents severe hyperglycemia that mandates insulin therapy according to current guidelines 1
• The ADA/EASD consensus specifically states that insulin is indicated when A1c exceeds 10%, particularly in the post-transplant setting where glycemic control directly impacts graft survival 1
• The current insulin dose (7 units Lantus) is actually quite low—this patient likely needs more insulin, not less

Post-Transplant Context Changes Risk-Benefit

• Kidney transplant recipients with diabetes have substantially elevated cardiovascular and graft failure risk 2
• Optimal A1c targets in diabetic kidney transplant recipients are 7.0-8.0% measured 1-2 years post-transplant, with mortality and cardiovascular benefits most pronounced in this range 2
• This patient at 10.2% is far above target and requires aggressive management

Metformin Monotherapy is Grossly Insufficient

• At 500 mg daily, metformin is at a subtherapeutic dose even for non-transplant patients
• Studies show metformin alone cannot achieve adequate control from A1c levels >10% 3
• The current regimen is already failing—removing insulin would worsen outcomes

What This Patient Actually Needs

Immediate Intensification Strategy

1. Increase basal insulin significantly: Current dose of 7 units is inadequate. A reasonable starting adjustment would be to 0.2 units/kg (approximately 15-20 units for most adults) 4

2. Optimize metformin dosing: Increase to at least 1000 mg twice daily if renal function permits (eGFR >45 mL/min/1.73m²) 5, 6

3. Consider adding a GLP-1 receptor agonist: This is the most practical solution for a patient lacking caregiver support:

   • Once-weekly dulaglutide has demonstrated superior glycemic control compared to MDI insulin in kidney transplant recipients, with A1c improvements of 0.5-0.6% and significant weight reduction 7
   • GLP-1RAs reduce injection burden while providing cardiovascular and graft protection 8
   • They offer better outcomes than basal-bolus insulin with less complexity 3, 7

Addressing the Caregiver Support Issue

The lack of caregiver support is a legitimate concern, but the solution is simplification, not abandonment of effective therapy:

• Once-weekly GLP-1RA (dulaglutide or semaglutide) + once-daily basal insulin + metformin provides excellent control with minimal complexity 7
• This regimen requires only 2 injections per week (1 GLP-1RA + 7 basal insulin doses)
• Pre-filled pens eliminate dosing errors and are easier to manage independently 4

Renal Function Considerations

• At 5 months post-transplant with fasting glucose 134 mg/dL, verify current eGFR before adjusting metformin
• If eGFR 30-45: reduce metformin to 500-1000 mg daily 5
• If eGFR <30: discontinue metformin 5
• Insulin and GLP-1RAs remain safe across all levels of kidney function 8

Critical Pitfalls to Avoid

1. Therapeutic inertia: The current A1c of 10.2% represents treatment failure—maintaining the status quo or reducing therapy is unacceptable 1

2. Underestimating transplant-specific risks: Poor glycemic control in kidney transplant recipients increases graft failure risk, cardiovascular events, and mortality 9, 2

3. Confusing patient preference with medical appropriateness: While patient autonomy matters, discharging on inadequate therapy when better options exist is not patient-centered care—it's abandonment

4. Ignoring modern therapeutic options: GLP-1RAs specifically address this patient's needs (simplicity, efficacy, weight management) and have proven benefits in transplant recipients 8, 7

Practical Discharge Plan

Recommended regimen:

• Insulin glargine 15-20 units once daily (titrate up by 2 units every 3 days until fasting glucose 100-130 mg/dL) 4
• Metformin 1000 mg twice daily (if eGFR >45) or 500 mg twice daily (if eGFR 30-45) 5, 6
• Add dulaglutide 1.5 mg subcutaneous once weekly 7

This provides a realistic 3-injection-per-week regimen (1 GLP-1RA + 7 basal insulin) that is manageable without caregiver support while addressing the severe hyperglycemia appropriately.

Target A1c: 7.0-8.0% within 3-6 months 2

5, 1, 4, 6, 3, 9, 2, 8, 7